BioSpace News Archive

Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming investor conferences.

Basilea Pharmaceutica Ltd. announced that it has entered into an asset purchase agreement with Twentyeight-Seven Therapeutics, Inc. for novel inhibitors of CLK kinases, developed by Basilea, that target aberrant splicing of RNA in cancer.

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-September 2022.

Verona Pharma plc, announces that senior management will participate in the following conferences in November 2022.

Evotec SE presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access.

Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that Thomas Willemsen, President and CEO, and Dr. Ivan D. Horak, Chief Medical Officer and Chief Scientific Officer, will present at the Stifel Healthcare Conference 2022.

Editas Medicine, Inc., a clinical stage genome editing company, reported business highlights and financial results for the third quarter of 2022.

Sotera Health Company announced that Alex Dimitrief is joining the Company as Senior Vice President and General Counsel.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that management will participate in four upcoming investor conferences.

Coeptis Therapeutics Holdings, Inc. today announced the appointment of new directors to the Company’s board of directors (the “Board”) following the completion of the previously announced business combination between Coeptis Therapeutics, Inc. and the Company and initiation of trading of the Company’s common stock and public warrants under the trading symbols COEP and COEPW on the Nasdaq Global Market.